Cover Image
市場調查報告書

肝細胞生長因子 (Hepatopoietin-A,Lung Fibroblast Derived Mitogen) :開發中產品分析

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363117
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
肝細胞生長因子 (Hepatopoietin-A,Lung Fibroblast Derived Mitogen) :開發中產品分析 Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 73 Pages
簡介

本報告提供肝細胞生長因子 (Hepatopoietin-A,Lung Fibroblast Derived Mitogen)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Kringle Pharma, Inc.
  • M3 Biotechnology, Inc.
  • Minerva Biotechnologies Corporation
  • Molecular Partners AG
  • ViroMed Co., Ltd.
  • Yooyoung Pharmaceutical Co., Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0578TDB

Summary

Global Markets Direct's, 'Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016', provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Overview
  • Therapeutics Development
    • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Stage of Development
    • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Therapy Area
    • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Indication
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Companies
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Products under Development by Universities/Institutes
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • AnGes MG, Inc.
    • F-star Biotechnology Limited
    • Kringle Pharma, Inc.
    • M3 Biotechnology, Inc.
    • Minerva Biotechnologies Corporation
    • Molecular Partners AG
    • ViroMed Co., Ltd.
    • Yooyoung Pharmaceutical Co., Ltd.
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate HGF for Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-0250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NK-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rilotumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-186 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YYB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Projects
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products
  • Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Featured News & Press Releases
    • Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences
    • Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy
    • Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease
    • Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
    • Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia
    • May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis
    • Apr 15, 2016: AnGes Completes Patient Enrollment for Phase 1/2 Clinical Trials of Gene Therapy with HGF Plasmid in Primary Lymphedema
    • Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study
    • Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma
    • Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer
    • Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference
    • Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer
    • Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia
    • Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
    • Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amgen Inc., H2 2016
  • Pipeline by AnGes MG, Inc., H2 2016
  • Pipeline by F-star Biotechnology Limited, H2 2016
  • Pipeline by Kringle Pharma, Inc., H2 2016
  • Pipeline by M3 Biotechnology, Inc., H2 2016
  • Pipeline by Minerva Biotechnologies Corporation, H2 2016
  • Pipeline by Molecular Partners AG, H2 2016
  • Pipeline by ViroMed Co., Ltd., H2 2016
  • Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top